PharmaCielo (PCLOF)
OTHER OTC:PCLOF
Want to see PCLOF full AI Analyst Report?
PCLOF Stock Chart & Stats
$0.01
<$0.01(6.14%)
At close: 4:00 PM EST
$0.01
<$0.01(6.14%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.12
Previous CloseN/A
Volume1.75K
Average Volume (3M)9.90K
Market Cap
$5.04M
Enterprise Value$27.76M
Total Cash (Recent Filing)$289.24K
Total Debt (Recent Filing)$18.65M
Price to Earnings (P/E)5.2
Beta-1.70
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding187,983,690
10 Day Avg. Volume17,743
30 Day Avg. Volume9,897
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market Cap5.50
Enterprise Value/Revenue10.63
Enterprise Value/Gross Profit36.70
Enterprise Value/Ebitda-27.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Standardized Cannabinoid ManufacturingPharmaCielo’s core B2B model of producing standardized cannabinoid inputs (CBD extracts, distillates, isolates) is structurally durable: supplying ingredients to medical and wellness manufacturers creates repeatable volume demand, allows scale in processing, and builds institutional customer relationships less sensitive to retail cycles.
Positive Gross Margin Profile (~29%)A positive gross margin indicates underlying unit economics that can support profitability if fixed costs are controlled and revenue scales. This suggests processing and extraction operations can generate margin contribution, making sustainable profitability achievable with stable demand and operational leverage.
Improving Cash Burn Versus Prior YearsReported reductions in cash burn and smaller operating outflows versus earlier years reflect progress in cost control and operational execution. Sustained improvement in cash generation reduces refinancing pressure and, if continued, would materially lower solvency risk and support reinvestment in scalable processing capabilities.
Bears Say
Declining And Volatile RevenueA persistent revenue decline and sales volatility undermine the firm’s ability to cover fixed processing and cultivation costs and limits operating leverage. Without consistent top-line growth, margin improvements and cash-flow stabilization remain tenuous and make long-term planning and customer retention harder.
Deep Operating And Net LossesSeverely negative EBIT and net margins indicate the current cost structure and revenue base do not support profitable operations. Persistent, large losses erode equity, consume cash, and require external funding; they also limit capacity to invest in growth or scale production to realize unit-economy benefits.
Stressed Balance Sheet And High LeverageNegative equity and debt materially exceeding the asset base signal elevated refinancing and solvency risk. A highly leveraged capital structure reduces financial flexibility, increases cost of capital, and makes the company vulnerable to funding shortfalls if cash-generation improvements stall or markets tighten.
PharmaCielo News
PCLOF FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was <$0.01 and its highest was $0.12 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is $5.04M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is May 04, 2026 which is in 16 days.
How were PharmaCielo’s earnings last quarter?
PharmaCielo released its earnings results on Mar 02, 2026. The company reported $0.001 earnings per share for the quarter, beating the consensus estimate of N/A by $0.001.
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 187,983,690 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
PharmaCielo reported an EPS of $0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in PCLOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Ownership Overview
16.47% Insiders
0.18% Other Institutional Investors
83.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---